Methoxsalen

Generic Name: Methoxsalen

Brand Names: Oxsoralen, Uvadex

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₈O_₄

CAS Number: 298-81-7

Unique Ingredient Identifier: U4VJ29L7BQ

Background: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.

Indication: For the treatment of psoriasis and vitiligo

Associated Conditions: Cutaneous T-Cell Lymphoma (CTCL), Refractory Cutaneous T-cell Lymphoma, Vitiligo, Idiopathic Vitiligo, Severe Psoriasis

Associated Therapies: -

Clinical Trials

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

Phase 2

Not yet recruiting

Conditions: Immune-related Colitis

Interventions: Drug: Methoxsalen
Drug: Infliximab
Drug: Vedolizumab

First Posted Date: 2024-10-17

Last Posted Date: 2024-12-30

Lead Sponsor: Therakos, LLC, a Mallinckrodt Company

Target Recruit Count: 30

Registration Number: NCT06646016

Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHD

Phase 2

Not yet recruiting

Conditions: Graft Vs Host Disease

Interventions: Drug: Steroids
Drug: Uvadex

First Posted Date: 2023-11-15

Last Posted Date: 2023-11-15

Lead Sponsor: Central Hospital, Nancy, France

Target Recruit Count: 42

Registration Number: NCT06133192

Locations: 🇫🇷
CHRU de Nancy, Vandoeuvre Les Nancy, France

Extracorporeal Photopheresis in Sezary Syndrome

Recruiting

Conditions: Sezary Syndrome

Interventions: Device: Extracorporeal photopheresis (ECP)
Drug: Methoxsalen Injection

First Posted Date: 2021-12-15

Last Posted Date: 2025-01-08

Lead Sponsor: Oleg E. Akilov, MD, PhD

Target Recruit Count: 15

Registration Number: NCT05157581

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis

Phase 2

Not yet recruiting

Conditions: Diffuse Cutaneous Systemic Sclerosis

Interventions: Device: Extracorporeal Photopheresis (ECP)
Drug: UVADEX

First Posted Date: 2021-08-03

Last Posted Date: 2024-11-25

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 15

Registration Number: NCT04986605

Locations: 🇨🇦
Rheumatology Clinic, St. Joseph's Health Care, London, Ontario, Canada

Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease

Phase 2

Recruiting

Conditions: Acute-graft-versus-host Disease

Interventions: Drug: Uvadex

First Posted Date: 2020-03-02

Last Posted Date: 2024-02-09

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 72

Registration Number: NCT04291261

Locations: 🇦🇹
Medical University of Vienna, Department of Medicine I, Vienna, Austria
🇦🇹
Medical University of Graz, Department of Internal Medicine, Graz, Austria
🇩🇪
University Hospital Erlangen, Erlangen, Germany

and more 2 locations

Study of Photopheresis in the Treatment of Erythrodermic MF and SS

Phase 2

Withdrawn

Conditions: Lymphoma, T-Cell, Cutaneous
Mycosis Fungoides/Sezary Syndrome

Interventions: Drug: Methoxsalen
Device: THERAKOS CELLEX Photopheresis System

First Posted Date: 2018-06-20

Last Posted Date: 2021-09-08

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT03563040

Locations: 🇨🇭
UniversitaetsSpital Zurich - Division of Dermatology, Zürich, Switzerland

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

Phase 3

Terminated

Conditions: Steroid Refractory Acute Graft Versus Host Disease

Interventions: Drug: Methoxsalen
Procedure: Extracorporeal Photopheresis (ECP)

First Posted Date: 2015-08-17

Last Posted Date: 2020-09-11

Lead Sponsor: Therakos, Inc., a Mallinckrodt Company

Target Recruit Count: 29

Registration Number: NCT02524847

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
University Hospitals Rainbow Babies & Children's, Cleveland, Ohio, United States

and more 29 locations

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

Phase 2

Terminated

Conditions: Chronic Graft vs. Host Disease
Graft vs Host Disease
Graft-Versus-Host Disease

Interventions: Procedure: Extracorporeal Photopheresis (ECP)
Drug: Methoxsalen

First Posted Date: 2014-12-23

Last Posted Date: 2020-03-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT02322190

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

PUVA Maintenance Therapy in Mycosis Fungoides

Phase 3

Completed

Conditions: Patch/Plaque Stage Mycosis Fungoides

Interventions: Drug: 8-methoxypsoralen

First Posted Date: 2012-09-18

Last Posted Date: 2018-11-14

Lead Sponsor: Medical University of Graz

Target Recruit Count: 28

Registration Number: NCT01686594

Locations: 🇦🇹
Department of Dermatology, Medical University of Vienna, Vienna, Austria
🇦🇹
Department of Dermatology, Hospital Hietzing, Vienna, Austria
🇦🇹
Department of Dermatology, Klinikum Wels, Wels, Austria

and more 6 locations

Extracorporal Photopheresis Pilot Study

Phase 1

Conditions: Hematological Malignancies

Interventions: Drug: methoxsalen
Procedure: Extracoporal Photopheresis (ECP)

First Posted Date: 2009-06-30

Last Posted Date: 2013-04-24

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 20

Registration Number: NCT00930566

Locations: 🇫🇷
Centre de Santé - Etablissement Français du Sang (EFS), Lyon, France
🇫🇷
Hôpital Edouard Herriot, Service d'Hématologie, Lyon, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy